iti-007 Report issue

Small molecule Experimental
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now
Lumateperone (ITI-722/ITI-007) is a dual 5HT2A receptor antagonist/dopamine phosphoprotein modulator (DPPM) for the treatment of schizophrenia. It is an orally available compound which combines potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathways downstream of dopamine receptors. Lumateperone was developed by Intra-Cellular Therapies, Inc., and is being evaluated for the treatment of schizophrenia and bipolar depression. In 3 efficacy studies in patients with acute schizophrenia, lumateperone was well-tolerated with a favorable safety profile, and in 2 studies of 3 demonstrated significantly superior efficacy over placebo.   NCATS

Chemistry

  • SMILES: CN1CCN2[C@H]3CCN(CCCC(=O)C4=CC=C(F)C=C4)C[C@H]3C5=C2C1=CC=C5
  • InChIKey: HOIIHACBCFLJET-SFTDATJTSA-N
  • Mol. Mass: 393.497
  • ALogP: Missing data
  • ChEMBL Molecules:
    None  
    None  
More Chemistry

Pharmacology

Alternative names

iti-007

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Alzheimer Disease (Phase 3)

Bipolar Disorder (Phase 3)

Schizophrenia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue